Saniona AB (publ) (STO: SANION)

Market Cap	908.51M
Revenue (ttm)	26.66M
Net Income (ttm)	-87.17M
Shares Out	111.89M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,440
Open	8.06
Previous Close	8.07
Day's Range	7.58 - 8.31
52-Week Range	1.74 - 8.44
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Pr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 23
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION

Financial Performance

In 2023, Saniona AB's revenue was 16.84 million, an increase of 10.19% compared to the previous year's 15.28 million. Losses were -95.81 million, -54.71% less than in 2022.